Nonprofit · EIN 81-2849764
GLIOBLASTOMA FOUNDATION INC
Tax-exempt · DURHAM, NC 27705
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $2,055,218 | $1,833,664 | $221,554 | $3,662,658 | $496,171 | $3,166,487 |
| December 31, 2023 | 990 | $1,699,784 | $1,411,492 | $288,292 | $2,482,026 | $0 | $2,482,026 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $1,964,537
- Program service revenue
- $0
- Investment income
- $2,803
- Net gain from sales of assets
- -$20,083
- Net income from fundraising events
- $87,878
- Other revenue
- $87,878
Expenses
- Grants and similar amounts paid
- $97,474
- Compensation of officers, directors and key employees
- $343,048
- Other salaries and wages
- $313,484
- Salaries, compensation and benefits (total)
- $696,475
- Professional fundraising fees
- $0
- Legal fees
- $109,886
- Accounting fees
- $33,284
- Travel
- $69,379
- Depreciation
- $56,674
- Program services (functional)
- $1,581,752
- Management and general (functional)
- $237,982
- Fundraising (functional)
- $13,930
Balance sheet and other
- Total assets, start of year
- $2,482,026
- Total assets, end of year
- $3,662,658
- Total liabilities, end of year
- $496,171
- Net assets, end of year
- $3,166,487
- Land, buildings and equipment
- $147,413
- Net assets without donor restrictions
- $3,166,487
- Gross receipts
- $2,251,075
- Employees
- 21
- Volunteers
- 150
- Year formed
- 2016
- State of legal domicile
- NC
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| GITA KWATRA | CEO Trustee or director, Officer | 40 | $291,500 | $51,548 |
| NEELAM KWATRA | PRESIDENT Trustee or director, Officer | 20 | $0 | $0 |
| MADAN KWATRA | TREASURER/SECRETARY Trustee or director, Officer | 4 | $0 | $0 |
| CAMERON WEST | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
| BRIAN AUSTIN | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
990 for the year ended December 31, 2023: 5 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| GITA KWATRA | CEO Trustee or director, Officer | 40 | $300,000 | $36,015 |
| NEELAM KWATRA | PRESIDENT Trustee or director, Officer | 20 | $0 | $0 |
| MADAN KWATRA | TREASURER/SECRETARY Trustee or director, Officer | 4 | $0 | $0 |
| CAMERON WEST | BOARD MEMBER Trustee or director, Officer | 1 | $0 | $0 |
| BRIAN AUSTIN | BOARD MEMBER Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 2451 CROASDAILE FARM PKWY STE 109, DURHAM, NC 27705-1466
- Principal officer (990 for 2024)
- MADAN KWATRA, 2451 CROASDAILE FARM PARKWAY 109, DURHAM, NC 27705
- Signed the 990
- MADAN KWATRA, SECRETARY/TREASURER
- Phone
- (919) 309-1489
- Return prepared by
- WILLIAMS OVERMAN PIERCE LLP
Mission
THE GLIOBLASTOMA FOUNDATION IS DEDICATED TO FINDING A CURE FOR GLIOBLASTOMA BY FUNDING RESEARCH AND DRUG DEVELOPMENT, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS DEVASTATING BRAIN CANCER. THROUGH THESE INTEGRATED PROGRAMS, THE FOUNDATION ACCELERATES SCIENTIFIC DISCOVERY, EMPOWERS PATIENTS WITH INFORMATION AND RESOURCES, AND EDUCATES THE PUBLIC ABOUT THE URGENT NEED FOR BETTER TREATMENTS AND IMPROVED OUTCOMES.
Program accomplishments
- RESEARCH AND DRUG DEVELOPMENT:IN 2024, THE GLIOBLASTOMA FOUNDATION ADVANCED ITS RESEARCH MISSION BY ACQUIRING LISAVANBULIN, A PROMISING TARGETED THERAPY FROM BASILEA PHARMACEUTICA, FOR FURTHER CLINICAL DEVELOPMENT IN GLIOBLASTOMA. THIS ACQUISITION MARKED A CRITICAL STEP TOWARD BRINGING PATIENTS NEW, MORE EFFECTIVE TREATMENTS. THE FOUNDATION ALSO SUPPORTED INVESTIGATOR-INITIATED RESEARCH ON MOLECULAR CHARACTERIZATION AND FUNCTIONAL PRECISION ONCOLOGY. ADDITIONALLY, THE FOUNDATION ESTABLISHED GLIOLAB, A CLIA-REGISTERED GENOMIC LABORATORY THAT WILL PROVIDE STATE-OF-THE-ART TESTING TO ACCELERATE DISCOVERY OF TARGETED THERAPIES BASED ON EACH TUMOR'S GENOMIC AND EPIGENOMIC PROFILE.Expenses $527,251 · grants $97,474
- PATIENT SUPPORT AND EDUCATION:THROUGHOUT 2024, THE FOUNDATION PROVIDED SUPPORT SERVICES FOR GLIOBLASTOMA PATIENTS AND CAREGIVERS NATIONWIDE, INCLUDING PERSONALIZED CLINICAL-TRIAL MATCHING, PROFESSIONALLY LED VIRTUAL SUPPORT GROUPS, AND EDUCATIONAL RESOURCES ON TREATMENT OPTIONS AND EMERGING RESEARCH. THESE PROGRAMS EMPOWERED PATIENTS TO MAKE INFORMED CARE DECISIONS AND FOSTERED A SENSE OF COMMUNITY AMONG FAMILIES AFFECTED BY THIS RARE DISEASE. HUNDREDS OF PATIENTS AND CAREGIVERS BENEFITED FROM THESE FREE SERVICES DURING THE YEAR.Expenses $527,251
- PUBLIC AWARENESS AND ADVOCACY:THE FOUNDATION LED NATIONWIDE EFFORTS TO RAISE AWARENESS AND ADVOCACY FOR THOSE AFFECTED BY GLIOBLASTOMA. IN 2024, IT ORGANIZED GLIOBLASTOMA AWARENESS DAY AND CONTINUED THE VOICES OF GLIOBLASTOMA PODCAST WHILE PLANNING TO EXPAND THE SERIES IN FUTURE YEARS TO FEATURE ADDITIONAL PATIENT, CAREGIVER, AND SCIENTIST PERSPECTIVES. THE FOUNDATION ALSO PARTNERED WITH EVENTS SUCH AS THE LOS ANGELES MARATHON TO INCREASE PUBLIC UNDERSTANDING AND SUPPORT FOR RESEARCH. THESE INITIATIVES EDUCATED THOUSANDS AND INSPIRED HOPE WITHIN THE GLIOBLASTOMA COMMUNITY.Expenses $527,250
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 81-2849764
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2016
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H30)
- Assets (IRS master file)
- $3,662,658
- Income (IRS master file)
- $2,251,075
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $2,055,218 | $1,833,664 | $3,662,658 | XML |
| 990 | December 2023 | $1,699,784 | $1,411,492 | $2,482,026 | XML |
| 990 | December 2022 | $1,471,550 | $853,578 | $1,781,399 | IRS |
| 990 | December 2021 | $1,253,574 | $703,351 | $1,523,936 | IRS |
| 990 | December 2020 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 81-2849764).
Questions about GLIOBLASTOMA FOUNDATION INC
- What is the EIN of GLIOBLASTOMA FOUNDATION INC?
- The employer identification number (EIN) of GLIOBLASTOMA FOUNDATION INC is 81-2849764.
- Is GLIOBLASTOMA FOUNDATION INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2016.
- Are donations to GLIOBLASTOMA FOUNDATION INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does GLIOBLASTOMA FOUNDATION INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of GLIOBLASTOMA FOUNDATION INC due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did GLIOBLASTOMA FOUNDATION INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of GLIOBLASTOMA FOUNDATION INC?
- The 990 for the year ended December 31, 2024 names MADAN KWATRA.
- Who are the officers and directors of GLIOBLASTOMA FOUNDATION INC?
- The 990 for the year ended December 31, 2024 lists 5 people; 1 received compensation from the organization, the highest $291,500 (GITA KWATRA, CEO).
- How much revenue does GLIOBLASTOMA FOUNDATION INC have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $2,055,218, expenses of $1,833,664 and total assets of $3,662,658 at year end.
Other nonprofits in DURHAM
- CHORDOMA FOUNDATION EIN 20-8423943 · last filed 990 for 2025
- RARE CANCER RESEARCH FOUNDATION EIN 46-3405526 · last filed 990 for 2025
- SOCIETY FOR TRANSLATIONAL ONCOLOGY INC EIN 20-3186261 · last filed 990 for 2025
- DUKE MEDICINE GLOBAL SUPPORT CORP EIN 61-1593721 · last filed 990 for 2025
- VOA FOUNDATION EIN 88-1907540 · last filed 990-EZ for 2025
- INTERNATIONAL CANCER CARE & RESEARCH EXCELLENCE FOUNDATION INC EIN 47-3821684 · last filed 990-EZ for 2025
- WPLAB INC EIN 86-1413357 · last filed 990 for 2025
- CHAMP FOUNDATION EIN 47-5555752 · last filed 990 for 2024
All nonprofits in DURHAM · North Carolina · Medical research